natgillin/translations-raw huggingface dataset:
By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer’s disease.
Memantin z zaviranjem receptorjev NMDA izboljša prenos signalov v možganih in zmanjša simptome Alzheimerjeve bolezni.
By blocking NMDA receptors, memantine improves the transmission of signals in the brain and reduces the symptoms of Alzheimer’s disease.
Memantin z zaviranjem receptorjev NMDA izboljšuje prenos signalov v možganih in zmanjšuje simptome Alzheimerjeve bolezni.
By blocking PCSK9, Praluent increases the number of receptors available to help remove the “bad” cholesterol – this lowers your “bad” cholesterol levels.
Z blokiranjem PCSK9 zdravilo Praluent poveča število razpoložljivih receptorjev, tako pomaga odstraniti "slabi" holesterol in s tem zniža njegovo koncentracijo.
By blocking PD-1, pembrolizumab prevents switching off these immune cells, thereby increasing the ability of the immune system to kill the cancer cells.
Z zaviranjem receptorja PD1 prepreči, da bi ta izklopil navedene imunske celice, s čimer poveča sposobnost imunskega sistema za uničevanje rakavih celic.
By blocking reverse transcriptase, Stribild reduces the amount of HIV-1 in the blood and keeps it at a low level.
Zdravilo Stribild blokira reverzno transkriptazo, s tem pa zmanjša količino virusa HIV-1 v krvi in ga vzdržuje na nizki ravni.
By blocking the action of PDE4, roflumilast reduces the inflammation in the lungs, helping to reduce the patient’s symptoms or to prevent them from getting worse.
Ker roflumilast zavira delovanje PDE4, zmanjša vnetje pljuč, kar pripomore k zmanjšanju bolnikovih simptomov ali prepreči njihovo poslabšanje.
By blocking the action of SGLT2, canagliflozin causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.
Kanagliflozin z zaviranjem delovanja prenašalca SGLT2 povzroči večje izločanje glukoze z urinom, kar zniža ravni glukoze v krvi.
By blocking the action of SGLT2, dapagliflozin causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.
Dapagliflozin z zaviranjem delovanja prenašalca SGLT2 povzroči večje izločanje glukoze z urinom, kar zniža ravni glukoze v krvi.
By blocking the action of SGLT2, Edistride causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.
Zdravilo Edistride z zaviranjem delovanja te beljakovine povzroči večje izločanje glukoze z urinom, kar zniža ravni glukoze v krvi.
By blocking the action of SGLT2, Forxiga causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.
Zdravilo Forxiga zavira delovanje prenašalca SGLT2 in tako povzroči večje izločanje glukoze z urinom, kar zmanjša raven glukoze v krvi.
By blocking the action of SGLT2, Jardiance causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.
Zdravilo Jardiance z zaviranjem delovanja te beljakovine povzroči večje izločanje glukoze z urinom, kar zniža ravni glukoze v krvi.
By blocking the action of the abnormal BRAF, Tafinlar helps to slow down the growth and spread of the cancer.
Zdravilo Tafinlar z zaviranjem delovanja neobičajne beljakovine BRAF prispeva k upočasnitvi rasti in širjenja raka.
By blocking the action of these enzymes, Stivarga helps to restrict the growth and spread of the cancer.
Zdravilo Stivarga z zaviranjem delovanja teh encimov pripomore k omejitvi rasti in širjenja raka.
By blocking the action of these enzymes, tazobactam allows ceftolozane to act against bacteria that would otherwise be resistant.
Z zaviranjem delovanja teh encimov tazobaktam omogoča ceftolozanu, da učinkovito deluje proti bakterijam, ki bi sicer bile odporne.
By blocking the action of this protein, empagliflozin causes more glucose to be removed via the urine, thereby reducing the levels of glucose in the blood.
Empagliflozin z zaviranjem delovanja te beljakovine povzroči večje izločanje glukoze z urinom, kar zniža ravni glukoze v krvi.
By blocking the activity of EGF receptors, the cancer cells no longer receive the messages needed for growth and multiplication.
S preprečevanjem aktivnosti receptorjev EGF rakave celice več ne sprejemajo sporočil, potrebnih za rast in razmnoževanje.
By blocking the activity of IL-1 beta, Ilaris may lead to an improvement in these symptoms.
Z zaviranjem delovanja IL-1 beta lahko zdravilo Ilaris olajša navedene simptome.
By blocking the activity of IL-1 beta, Ilaris may lead to an improvement in these symptoms.
Z zaviranjem delovanja IL-1 beta lahko zdravilo Ilaris povzroči izboljšanje navedenih simptomov.
By blocking the activity of IL-1 beta, Ilaris may lead to an improvement in these symptoms.
Z zaviranjem delovanja IL-1 beta lahkozdravilo Ilaris olajša navedene simptome.
By blocking the activity of these enzymes in cancer cells, the medicine reduces the growth and spread of the cancer.
Z zaviranjem delovanja teh encimov v rakavih celicah zdravilo zmanjša rast in širjenje raka.
By blocking the activity of these proteins, nintedanib can help stop the growth and spread of the cancer.
S preprečevanjem aktivnosti teh beljakovin lahko nintedanib zavre rast in širjenje rakavih celic.
By blocking the activity of VEGF receptors, the medicine reduces the blood supply to the cancer cells, slowing down the cancer’s growth.
S preprečevanjem aktivnosti receptorjev VEGF zdravilo zmanjša oskrbo rakavih celic s krvjo in upočasni rast raka.
By blocking the C5 complement protein, eculizumab prevents complement proteins from damaging the blood cells, thereby helping to relieve the symptoms of the disease.
Ekulizumab z zaviranjem beljakovine komplementa C5 preprečuje, da bi njegova beljakovina poškodovala krvne celice, kar pomaga lajšati simptome bolezni.
By blocking the effect of endothelin, Volibris allows the vessels to dilate (expand), helping to lower the blood pressure and improving symptoms.
Zdravilo Volibris z zaviranjem učinka endotelina omogoči širjenje žil, kar prispeva k znižanju krvnega tlaka in olajšanju simptomov.
By blocking the effect of ET-1, Thelin allows the vessels to dilate (expand), helping to lower the blood pressure and improving symptoms.
Zdravilo Thelin z zaviranjem učinka hormona ET–1 dilatira (razširi) žile, kar pomaga pri zniževanju krvnega tlaka in izboljšanju simptomov.
By blocking the effect of LHRH, Cetrotide stops the production of LH, and therefore prevents premature ovulation, which can result in the release of eggs that are immature and unsuitable for use in techniques such as in vitro fertilisation (IVF).
Zdravilo Cetrotide z zaviranjem učinka LHRH ustavi tvorjenje LH in tako prepreči prezgodnjo ovulacijo, ki ima lahko za posledico sprostitev jajčec, ki niso dozorela ali pa so neprimerna za uporabo pri tehnikah, kot je oploditev in-vitro (IVF).
By blocking the protein Slentrol decreases the absorption of fats from the gut and this change in fat absorption has an appetite suppressant effect.
Z zaviranjem beljakovine zdravilo Slentrol zniža absorpcijo maščob iz črevesja, ta sprememba pa potlači tek.
By blocking the protein Yarvitan decreases the absorption of fats from the gut.
Ko zdravilo Yarvitan blokira beljakovino, se absorpcija maščob iz črevesja zmanjša.
By blocking the receptor to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to expand.
Ker telmisartan zavira receptorje, na katere se angiotenzin II običajno veže, hormonu prepreči delovanje, zaradi česar se krvne žile razširijo.
By blocking the receptors to which angiotensin II normally attaches, azilsartan medoxomil stops the hormone from having an effect,
Medoksomilazilsartanat z zaviranjem receptorjev, na katere se angiotenzin II običajno veže, zaustavlja delovanje tega hormona, zaradi
By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone’s harmful effects on the heart and it also reduces blood pressure by allowing blood vessels to widen.
Z blokado receptorjev, na katere se običajno veže angiotenzin II, valsartan prepreči škodljive učinke hormona na srce in s širjenjem žil zmanjša krvni tlak.
By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone’s harmful effects on the heart and it also reduces blood pressure by allowing blood vessels to widen.
Z blokado receptorjev, na katere so običajno veže angiotenzin II, valsartan prepreči škodljive učinke hormona na srce in s širjenjem žil zmanjša krvni tlak.
By blocking their action, Bosulif helps to control cell division, thereby controlling the growth and spread of the leukaemia cells in CML.
Zdravilo Bosulif z zaviranjem njihovega delovanja pomaga nadzirati celično delitev, s tem pa nadzira rast in širjenje levkemičnih celic pri kronični mieloični levkemiji.
By blocking their action, tazobactam makes ceftolozane more effective at killing bacteria.
Z zavrtjem njihovega delovanja tazobaktam doseže, da ceftolozan učinkoviteje uniči bakterije.
By blocking these enzymes,
Zdravilo Rivastigmine
By blocking these enzymes, Exelon allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia associated with Parkinson’s disease.
Zdravilo Exelon z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
By blocking these enzymes, Exelon allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Exelon z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Exelon allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease.
Zdravilo Exelon z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni.
By blocking these enzymes, lenvatinib can block the formation of new blood vessels and hence cut off the blood supply that keeps cancer cells growing, and reduce their growth.
Lenvatinib z zaviranjem teh encimov prepreči nastajanje novih krvnih žil, s čimer prekine dotok krvi, ki omogoča rast rakavih celic, in zmanjša njihovo rast.
By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia due to Parkinson’s disease.
Zdravilo Nimvastid z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi alzheimerjeve demence in demence zaradi parkinsonove bolezni ublažijo.
By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Nimvastid z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Prometax allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia associated with Parkinson’s disease.
Zdravilo Prometax z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
By blocking these enzymes, Prometax allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Prometax z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Prometax allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease.
Zdravilo Prometax z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni.
By blocking these enzymes, Rivastigmine 1 A Pharma allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia due to Parkinson’s disease.
Zdravilo Rivastigmine 1 A Pharma z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
By blocking these enzymes, Rivastigmine 1 A Pharma allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Rivastigmin 1 A Pharma z blokiranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence, v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Rivastigmine 3M Health Care Ltd allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia.
Zdravilo Rivastigmin 3M Health Care Ltd z zaviranjem teh encimov povzroči, da se ravni acetilholina v možganih zvišajo, zaradi česar se simptomi Alzheimerjeve demence ublažijo.
By blocking these enzymes, Rivastigmine 3M Health Care Ltd. allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease.
Zdravilo Rivastigmin 3M Health Care Ltd. z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni.
By blocking these enzymes, Rivastigmine Actavis allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Rivastigmin Actavis z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Rivastigmine Actavis allows levels of acetylcholine to increase in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia due to Parkinson’s disease.
Zdravilo Rivastigmine Actavis z zaviranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi alzheimerjeve demence in demence zaradi parkinsonove bolezni ublažijo.
By blocking these enzymes, Rivastigmine allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Rivastigmin HEXAL z blokiranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence, v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Rivastigmine Hexal allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia due to Parkinson’s disease.
Zdravilo Rivastigmine Hexal z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
By blocking these enzymes, Rivastigmine HEXAL allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Rivastigmin HEXAL z blokiranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence, v povezavi s Parkinsonovo boleznijo.
By blocking these enzymes, Rivastigmine Sandoz allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s dementia and dementia due to Parkinson’s disease.
Zdravilo Rivastigmine Sandoz z blokiranjem teh encimov omogoča, da se ravni acetilholina v možganih povečajo, zaradi česar se simptomi Alzheimerjeve demence in demence zaradi Parkinsonove bolezni ublažijo.
By blocking these enzymes, Rivastigmine Sandoz allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer’s disease and dementia associated with Parkinson’s disease.
Zdravilo Rivastigmin Sandoz z blokiranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence, v povezavi s Parkinsonovo boleznijo.
By blocking these proteins, the medicine prevents the hepatitis C virus from multiplying and infecting new cells.
Z zaviranjem teh beljakovin zdravilo prepreči virusu hepatitisa C, da bi se razmnoževal in okužil nove celice.
By blocking these receptors, Imatinib Accord helps to control cell division.
Z zaviranjem teh receptorjev zdravilo Imatinib Accord prispeva k nadzoru nad delitvijo celic.
By blocking these receptors, Imatinib Actavis helps to control cell division.
Z zaviranjem teh receptorjev zdravilo Imatinib Actavis prispeva k nadzoru delitve celic.
By blocking these receptors, Ivemend can prevent nausea and vomiting, which often happens during and after chemotherapy.
Zdravilo Ivemend lahko z zaviranjem teh receptorjev prepreči slabost in bruhanje, ki se pogosto pojavita med kemoterapijo in po njej.
By blocking these receptors, Relistor reduces the constipation due to opioids, but does not interfere with their painkilling effects.
Z zaviranjem teh receptorjev zdravilo Relistor zmanjšuje zaprtost zaradi opioidov, vendar ne vpliva na njihovo protibolečinsko delovanje.
By blocking these receptors, Tyverb helps to control cell division and growth of the cancer.
Zdravilo Tyverb z zaviranjem teh receptorjev prispeva k nadzoru nad celično delitvijo in širjenjem raka.
By blocking this enzyme, Intelence, taken in combination with other anti-HIV medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Intelence, ki se jemlje skupaj z drugimi zdravili za zdravljenje okužbe z virusom HIV, z zaviranjem tega encima zmanjša koncentracijo virusa HIV v krvi in jo ohranja na nizki ravni.
By blocking this enzyme, Stocrin, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Z zaviranjem tega encima zdravilo Stocrin, ki se jemlje v kombinaciji z drugimi protivirusnimi zdravili, zmanjša količino virusa HIV v krvi in jo ohranja na nizki ravni.
By blocking this enzyme, Sustiva, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Z zaviranjem tega encima zdravilo Sustiva, ki se jemlje v kombinaciji z drugimi protivirusnimi zdravili, zmanjša količino virusa HIV v krvi in jo ohranja na nizki ravni.
By blocking this factor, ranibizumab reduces the growth of the blood vessels and controls the leakage and swelling.
Ranibizumab zavira ta dejavnik in tako zmanjša rast krvnih žil ter nadzira prepuščanje in otekanje.
By blocking TNF-alpha, certolizumab pegol reduces the inflammation and other symptoms of the diseases.
Certolizumab pegol z zaviranjem TNF-alfa zmanjša vnetje in druge simptome teh bolezni.
By blocking TNF-alpha, infliximab improves the inflammation and other symptoms of the diseases.
Z zaviranjem TNF-alfa infliksimab ublaži vnetna stanja in druge simptome obolenj.
By blocking TNF-, golimumab reduces the inflammation and other symptoms of these diseases.
Golimumab z zaviranjem TNF- izboljša stanje vnetij in druge simptome teh bolezni.
By blocking two enzymes called ‘DNA gyrase’ and ‘topoisomerase IV’, pradofloxacin stops the bacteria from growing and multiplying.
Pradofloksacin ustavi rast in razmnoževanje bakterij z blokiranjem dveh encimov, ki ju imenujemo „DNA-giraza“ in „topoizomeraza IV“.
By BSA using the Mosteller formula the recommended oral dose for paediatric patients of all ages is 150 mg/m2 once daily for two weeks followed by 150 mg/m2 twice daily thereafter.
Priporočeni peroralni odmerek za otroke vseh starosti, določen na podlagi telesne površine po Mostellerjevi formuli je 150 mg/m2 enkrat na dan, dva tedna, nato sledi odmerjanje 150 mg/m2 dvakrat na dan.
By comparison, vorapaxar exposure (AUC and Cmax) is estimated to be 19-21% lower in patients with a body weight of >100 kg compared to those weighing 60-100 kg.
Na podlagi primerjave je ocenjeno, da je izpostavljenost vorapaksarju (AUC in Cmax) pri osebah s telesno maso > 100 kg od 19 do 21 % nižja kot pri tistih s telesno maso od 60 do 100 kg.
By competing with the natural substrate deoxyguanosine TP, entecavir-TP functionally inhibits the 3 activities of the viral polymerase: (1) priming of the HBV polymerase, (2) reverse transcription of the negative strand DNA from the pregenomic messenger RNA, and (3) synthesis of the positive strand HBV DNA.
Entekavir trifosfat s kompeticijo z naravnim substratom deoksigvanozin trifosfatom funkcionalno zavira 3 aktivnosti virusne polimeraze: (1) prileganje ("priming") polimeraze HBV, (2) reverzno transkripcijo negativne verige DNA iz pregenomske informacijske ("messenger") RNA in (3) sintezo pozitivne verige DNA HBV.
by conivaptan
konivaptanom
By continuously breathing the patient must pull out the straw and immediately close the sample tube with its stopper.
Medtem ko bolnik neprekinjeno izdihuje, izvlecite slamico in takoj zaprite epruveto s priloženim zamaškom.
By contrast, ventricular arrhythmias were reported with similar frequencies in patients without a history of CHF who were treated with either BRINAVESS or placebo (3.2% for BRINAVESS versus 3.6% for placebo).
V nasprotju s tem so bile prekatne motnje srčnega ritma pri bolnikih brez anamneze kongestivnega srčnega popuščanja enako pogosto opisane med uporabo zdravila BRINAVESS (3,2 %) kot placeba (3,6 %).
By Day 180 the mean retinal thickness reduction (-119.3 microns) compared with sham was not significant.
Srednje zmanjšanje debeline mrežnice do 180. dneva (–119,3 mikrona) v primerjavi s placebom ni bilo pomembno.
By Day 30, the incidence of all cause mortality was significantly reduced from 3.5% on enoxaparin to 2.9% on fondaparinux (hazard ratio 0.83, 95% CI, 0.71;0.97, p = 0.02).
Do 30. dne se je smrtnost iz kateregakoli vzroka pomembno zmanjšala – s 3,5 % pri enoksaparinu na 2,9 % pri fondaparinuksu (razmerje tveganja 0,83, 95 % interval zaupanja, 0,71;0,97, p = 0,02).
By Day 9, 1.1% of patients treated with fondaparinux and 1.4% of control patients experienced a severe haemorrhage.
Hujša krvavitev se je do 9. dne pojavila pri 1,1 % bolnikov, ki so se zdravili s fondaparinuksom in 1,4
By expanding these blood vessels, the blood pressure is reduced and symptoms are improved.
Z razširitvijo krvnih žil se tlak zmanjša in simptomi se izboljšajo.
By expanding these blood vessels, the blood pressure is reduced and symptoms are improved.
Z razširitvijo teh krvnih žil se krvni tlak zniža, simptomi pa se izboljšajo.
By extrapolation from clinical data on combination therapy with standard interferon in paediatric patients (negative predictive value 96 % for interferon alfa–2b/ribavirin), patients who fail to achieve virological response at 12 weeks are highly unlikely to become sustained virological responders.
Na podlagi ekstrapolacije podatkov iz kliničnih študij kombinirane terapije s standardnim interferonom pri pediatričnih bolnikih (negativna napovedna vrednost za uporabo interferona alfa-2b in ribavirina je 96 %) lahko sklepamo, da je pri tistih bolnikih, ki niso dosegli virološkega odziva do 12. tedna, zelo majhna verjetnost, da bodo kdaj dosegli trajen virološki odziv.